Patient-derived xenograft (PDX) model is a preclinical research tool used in cancer research and drug development. These models are created by implanting patient-derived tumor tissues from cancer patients into immunodeficient mice, which allows for the growth and study of human tumors in a controlled laboratory setting. These models play a crucial role in tumor biology studies, drug efficacy evaluation studies, and the prediction of patients’ responses to various treatments. They are particularly useful in the field of precision oncology, where treatments are tailored to individual patients based on their unique genetic profiles. The ability of PDX models to replicate the characteristics of human tumors makes them an indispensable tool in understanding tumor biology, developing targeted therapies, and advancing cancer research. The growing awareness of the advantages of humanized PDX models and the rising demand for personalized medicine are the other noteworthy factors contributing to the expansion of patient-derived xenograft model market size. However, significant operational costs associated with the PDX model hinder the patient-derived xenograft model market growth.
Rising Demand for Personalized Medicine Drives Patient-Derived Xenograft Model Market Growth
Personalized medicine involves tailoring treatment plans to individual patients on the basis of their genetic makeup, among other factors. This approach allows for highly targeted and effective treatments, as it considers the unique characteristics of each patient’s cancer. Before opting for this approach, thorough preclinical testing of potential therapies on patient-specific tumors is essential. The shift toward precision medicine and targeted therapies triggers the demand for patient-centric disease models. PDX models, which closely mimic the characteristics of tumors in human patients, provide a reliable platform for such testing. Pharmaceutical companies and research institutions use these models to evaluate the safety and efficacy of personalized therapies as well as to validate personalized treatment approaches. To deliver customized medication, personalized medicine involves creating custom medications by utilizing animal models. PDX models are prepared by transplanting human tissues to immunodeficient mice, and the disease expression is tracked in these models. To create tailored medications, the PDX model employed with pharmaceuticals and gene therapies is used to discover the appropriate treatment, thus generating suitable or personalized medicines, which propels the growth of the patient-derived xenograft model market.
Currently, cancer has a significant impact on the global healthcare system, and the development and manufacturing of cancer medicines has garnered a lot of interest. According to the GLOBOCAN Report 2020, ~19.29 million new cancer cases have been reported globally, along with 9.95 million reported deaths caused by the disease. The major cancer types affecting economies are breast cancer, lung cancer, prostate cancer, and colorectum cancer. As per the World Health Organization (WHO), ~2.3 million women were diagnosed with breast cancer, and 685,000 deaths were reported due to the disease in 2020. The International Agency for Research on Cancer projects that the incidence of breast cancer would increase by more than one-third in the coming years, resulting in ~3 million new cases per year by 2040. Annually, the number of deaths caused by this condition is likely to rise by more than 50% in the near future, resulting in a death count of ~1 million by 2040.
According to the WHO, Japan reported 1.02 million new cancer cases in 2020, and lung cancer was a leading type with 138,532 new cases reported in 2020. Moreover, breast cancer is the second most common cancer in Canada, with 1 out of every 8 women to be diagnosed with the condition in their lifetime. According to WHO estimates, 28,026 breast cancer cases were diagnosed in Canada in 2020. The growing burden of cancer is promoting the demand for personalized therapies worldwide. Strategies are being created to combat the burgeoning incidence of cancer and provide patients with effective in vivo and in vitro therapies. PDX models can be used to predict the efficacy of standard and cutting-edge anti-cancer therapeutics. These models facilitate the identification of individualized treatment strategies by reflecting the genetic and molecular characteristics of patient tumors. Therefore, these models become a critical component of personalized medicines and the growing popularity of personalized medicine bolsters the patient-derived xenograft model market growth.
Patient-Derived Xenograft Model Market: Segmental Overview
The patient-derived xenograft model market report is segmented on the basis of model type, tumor type, application, and end user. Based on model type, the market is categorized into mice models and rats models. The mice models segment held a significant patient-derived xenograft model market share in 2022. It is expected to register a higher CAGR in the market during 2022–2030. Factors such as the biological similarities in mice with human anatomies, wide availability of mice, high degree of reproducibility and standardization, well-established modeling techniques and cost-effectiveness of mice models, and the availability of immunodeficient strains of mice favor the growth of the market. The mice have a rapid reproductive cycle and a long lifespan (one mouse year equals 30 human years), making the price, time, and space needed for the study manageable.
Patient-Derived Xenograft Model Market: Competitive Landscape and Key Developments
Champions Oncology Inc., Charles River Laboratories Inc., Crown Bioscience Inc., EPO Berlin-Buch GmbH, Hera BioLabs, Horizon Discovery Group plc, Oncodesign, Pharmatest Services Ltd, Xentech SAS, and JSR Corporation are a few of the key companies operating in the market. These companies focus on product innovation strategies to meet evolving customer demands, along with maintaining their brand name in the patient-derived xenograft model market.
A few of the recent developments in the global patient-derived xenograft model market are mentioned below:
- In December 2022, Crown Bioscience, Inc., a JSR Life Sciences company, entered into a global licensing agreement with ERS Genomics Limited. This agreement provided Crown Bioscience full permission to operate globally using ERS’s foundational CRISPR/Cas9 patent portfolio for genetic editing. Under the terms of the agreement, Crown Bioscience widened its genetic modification capabilities.
- In November 2021, Inotiv Inc. completed the acquisition of Envigo RMS Holding Corp., a globally leading provider of research models and services.